Raymond James raised the firm’s price target on Tenet Healthcare (THC) to $200 from $185 and keeps an Outperform rating on the shares. Tenet’s Q2 results exceeded expectations, marking a strong quarter, but the stock move following the results “a bit surprising” and “overdone,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $188 from $180 at Guggenheim
- Tenet Healthcare price target raised to $238 from $230 at UBS
- Tenet Healthcare price target raised to $225 from $210 at Morgan Stanley
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare: Strategic Focus and Financial Performance Drive Buy Rating